Drug maker AbbVie today announced that it has reached a $63 billion transaction agreement under which it will acquire Allergan.
Drug maker AbbVie today announced that it has reached a $63 billion transaction agreement under which it will acquire Allergan.
“This is a transformational transaction for both companies and achieves unique and complementary strategic objectives,” said Richard A. Gonzalez, chairman and chief executive officer (CEO) of AbbVie, in a statement announcing the deal. “The combination of AbbVie and Allergan increases our ability to continue to deliver on our mission to patients and shareholders. With our enhanced growth platform to fuel industry-leading growth, this strategy allows us to diversify AbbVie’s business while sustaining our focus on innovative science and the advancement of our industry-leading pipeline well into the future.”
Under the deal, which is expected to close by early 2020, AbbVie will continue to be led by Gonzalez, and 2 members of the Allergan board, including chairman and CEO Brent Saunders, will join the AbbVie board.
According to AbbVie, the combination of the 2 companies’ portfolios and platforms will result in approximately $48 billion in combined 2019 revenue. The combined company should produce enough cash flow to continue growth and investment in its pipeline as well as reduction of debt.
The acquisition comes as AbbVie faces pressure on its flagship drug, Humira, which faced competition in Europe from biosimilar adalimumab for the first time in late 2018. While no adalimumab biosimilars are slated for US launches prior to 2023, the Humira maker has sought to mitigate the impact of biosimilars through the sales of novel agents.
Earlier this year, Michael Severino, vice chairman and president of AbbVie, told investors that non-Humira sales will be driven by AbbVie’s hematologic oncology drugs, as well by upadacitinib and risankizumab in the immunology space.
Allergan, too, has faced setbacks in the form of oncoming competition. The drug maker notably attempted to transfer its patents covering its dry-eye drug, Restasis, to the Saint Regis Mohawk Tribe for a bulk payout, plus the promise of annual royalties, in exchange for invoking sovereign immunity from inter partes review (IPRs). A United States Court of Appeals later ruled that sovereign immunity does not extend to IPRs, opening Allergan to patent challenges and subsequent competition for the top-selling drug.
Notably, Allergan also has a hand in biosimilar development; together with partner Amgen, Allergan recently announced positive topline results from a combined phase 1 and phase 3 study of a proposed biosimilar rituximab, and the partnership has received FDA approvals for a biosimilar trastuzumab, Kanjinti, and a biosimilar bevacizumab, Mvasi.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).